Clinical Trials › Cancer Clinical Trial › Hodgkin s Lymphoma Leukemia other Lymphoid Leukemia Multiple Myeloma Myeloid and Monocytic Leukemia › A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of a Non-Covalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS 062, in Patients With B-Lymphoid Malignancies

Print
A A A

COVID-19 and protecting your health ›

A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of a Non-Covalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS 062, in Patients With B-Lymphoid Malignancies

Protocol Number: UCI-16-95

NCT Number: NCT03037645

Condition/Disease: Cancer - Hodgkin's Lymphoma, Cancer - Leukemia, other, Cancer - Lymphoid Leukemia, Cancer - Multiple Myeloma, Cancer - Myeloid and Monocytic Leukemia, Cancer - Non-Hodgkin's Lymphoma, Cancer - Other Hematopoietic

Principal Investigator: Susan O'Brien

Status: Open

Treatment: Treatment

Phase: Ib/II

Age Group: Adult

Scope: Local

Learn More:
For information about cancer clinical trials at the UCI Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.